Literature DB >> 32354949

Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report.

Suguru Shirotake1, Yuta Umezawa2, Takashi Okabe2, G O Kaneko2, Kent Kanao2, Koshiro Nishimoto2, Masafumi Oyama2.   

Abstract

BACKGROUND/AIM: Patients with metastatic renal cell carcinoma (RCC) with cardiac metastasis have had poor outcomes in the era of molecular targeted therapy. There are few reported outcomes for patients with cardiac metastasis of RCC treated with immune checkpoint inhibitors (ICIs). CASE REPORT: A 32-year-old female presented with metastatic RCC (unclassified type) with contralateral renal and cardiac metastases, as well as renal hilar lymph node metastases (cT4N2M1). An 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) computed tomographic (CT) scan was useful in diagnosing cardiac metastasis. Nivolumab plus ipilimumab achieved prominent shrinkage of almost all tumors except for one cardiac tumor. FDG-PET/CT scan also revealed the marked attenuation of FDG uptake in each tumor. In addition, a needle biopsy of the remaining primary renal tumor was pathologically observed to have no viable cancer cells.
CONCLUSION: This successful case suggests that ICIs might provide a better outcome even for patients with cardiac metastasis of RCC, and that FDG-PET/CT scan might be useful for therapeutic assessment, as well as diagnosis. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  FDG-PET/CT scan; Renal cell carcinoma; cardiac metastasis; nivolumab plus ipilimumab

Mesh:

Substances:

Year:  2020        PMID: 32354949      PMCID: PMC7279812          DOI: 10.21873/invivo.11932

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  12 in total

Review 1.  Metastases to the heart.

Authors:  K Reynen; U Köckeritz; R H Strasser
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

2.  The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Authors:  Mariuxi A Viteri Malone; Gustavo Ruiz Ares; Guillermo De Velasco; Raphael Brandão; Xun Lin; Craig Norton; Ronit Simantov; Javid Moslehi; Katherine M Krajewski; Toni K Choueiri; Rana R McKay
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

3.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 4.  Cardiac metastases.

Authors:  R Bussani; F De-Giorgio; A Abbate; F Silvestri
Journal:  J Clin Pathol       Date:  2006-11-10       Impact factor: 3.411

5.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

6.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

7.  Histological complete response with nivolumab for renal cell carcinoma with multiple metastases: A case report.

Authors:  Suguru Shirotake; Go Kaneko; Koji Nagata; Masafumi Oyama; Koshiro Nishimoto
Journal:  Mol Clin Oncol       Date:  2018-11-28

8.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Authors:  Daniel Y Wang; Joe-Elie Salem; Justine V Cohen; Sunandana Chandra; Christian Menzer; Fei Ye; Shilin Zhao; Satya Das; Kathryn E Beckermann; Lisa Ha; W Kimryn Rathmell; Kristin K Ancell; Justin M Balko; Caitlin Bowman; Elizabeth J Davis; David D Chism; Leora Horn; Georgina V Long; Matteo S Carlino; Benedicte Lebrun-Vignes; Zeynep Eroglu; Jessica C Hassel; Alexander M Menzies; Jeffrey A Sosman; Ryan J Sullivan; Javid J Moslehi; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

9.  Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.

Authors:  Kambiz Rahbar; Harald Seifarth; Michael Schäfers; Lars Stegger; Andreas Hoffmeier; Tilmann Spieker; Klaus Tiemann; David Maintz; Hans Heinrich Scheld; Otmar Schober; Matthias Weckesser
Journal:  J Nucl Med       Date:  2012-05-10       Impact factor: 10.057

10.  Rare Case of Intracardiac Renal Cell Carcinoma Metastasis with Response to Nivolumab: Case Report and Literature Review.

Authors:  Jawaher Ansari; Sumaya Alhelali; Zakariya Albinmousa; Ashraf Farrag; Arwa M Ali; Mai Abdelgelil; Abdulaziz Alhamad; Ghormallah Alzahrani; Asif Ansari; John Glaholm
Journal:  Case Rep Oncol       Date:  2018-12-20
View more
  1 in total

1.  Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.

Authors:  Yuki Kobari; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; Hideki Ishida; Kazunari Tanabe; Toshio Takagi
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.